TY - JOUR
T1 - Changes in health-related quality of life with smoking cessation treatment
AU - Hays, J. Taylor
AU - Croghan, Ivana T.
AU - Baker, Christine L.
AU - Cappelleri, Joseph C.
AU - Bushmakin, Andrew G.
N1 - Funding Information:
This work was supported by Pfizer Inc which was the sponsor and funding source for both clinical trials reported here (NCT Identifier: NCT00143364 and NCT00141206).
Funding Information:
Editorial assistance in the form of proof reading, collation of review comments, formatting the manuscript for submission, preparation of figures and formatting of references was provided by Penny Gorringe, MSc, and Abegale Templar, PhD, of UBC Scientific Solutions and was funded by Pfizer Inc. Thanks to Darrell Schroeder (Mayo Clinic) for editorial assistance. Special thanks to the exceptional staff at each of the study sites for their patience and persistence in helping to collect and compile these data. In addition, the authors wish to thank the subjects who participated in this research programme.
PY - 2012/4
Y1 - 2012/4
N2 - Background: Cigarette smoking causes reduced health-related quality of life (QoL) and smoking abstinence improves health-related QoL. We assessed the effects of treatment for tobacco dependence on the health-related QoL in a 52-week randomized controlled trial of varenicline and bupropion sustained release (SR). Methods: Subjects who smoked ≥ 10 cigarettes per day for the past year were randomly assigned to receive varenicline 1mg twice daily (n=696), bupropion SR 150mg twice daily (n=671) or placebo (n=685) for 12 weeks and followed post-therapy for an additional 40 weeks. Health-related QoL was assessed using the Smoking Cessation Quality of Life questionnaire at baseline and Weeks 12, 24 and 52. Results: Health transition (perceived health compared with baseline) and self-control were both significantly improved among subjects receiving varenicline and bupropion SR compared with placebo at Weeks 12, 24 and 52. Similarly, varenicline-treated subjects had significantly improved health transition and self-control compared with subjects who received bupropion SR at Weeks 12 and 24, and at Week 52 for health transition. A significant positive association existed between length of continuous abstinence and improved health transition, vitality, self-control, anxiety and overall mental profile. In most instances both a direct and an indirect effect (through continuous smoking abstinence) of each active treatment (vs. placebo) contributed to improved self-control and health transition. Conclusion: Treatment with varenicline and bupropion SR for smoking cessation resulted in improved self-control and health transition that was mediated in large part by continuous smoking abstinence.
AB - Background: Cigarette smoking causes reduced health-related quality of life (QoL) and smoking abstinence improves health-related QoL. We assessed the effects of treatment for tobacco dependence on the health-related QoL in a 52-week randomized controlled trial of varenicline and bupropion sustained release (SR). Methods: Subjects who smoked ≥ 10 cigarettes per day for the past year were randomly assigned to receive varenicline 1mg twice daily (n=696), bupropion SR 150mg twice daily (n=671) or placebo (n=685) for 12 weeks and followed post-therapy for an additional 40 weeks. Health-related QoL was assessed using the Smoking Cessation Quality of Life questionnaire at baseline and Weeks 12, 24 and 52. Results: Health transition (perceived health compared with baseline) and self-control were both significantly improved among subjects receiving varenicline and bupropion SR compared with placebo at Weeks 12, 24 and 52. Similarly, varenicline-treated subjects had significantly improved health transition and self-control compared with subjects who received bupropion SR at Weeks 12 and 24, and at Week 52 for health transition. A significant positive association existed between length of continuous abstinence and improved health transition, vitality, self-control, anxiety and overall mental profile. In most instances both a direct and an indirect effect (through continuous smoking abstinence) of each active treatment (vs. placebo) contributed to improved self-control and health transition. Conclusion: Treatment with varenicline and bupropion SR for smoking cessation resulted in improved self-control and health transition that was mediated in large part by continuous smoking abstinence.
UR - http://www.scopus.com/inward/record.url?scp=84859792880&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859792880&partnerID=8YFLogxK
U2 - 10.1093/eurpub/ckq137
DO - 10.1093/eurpub/ckq137
M3 - Article
C2 - 20884658
AN - SCOPUS:84859792880
SN - 1101-1262
VL - 22
SP - 224
EP - 229
JO - European Journal of Public Health
JF - European Journal of Public Health
IS - 2
ER -